Ensysce Biosciences Inc. (ENSC)
Ensysce Biosciences Provides Enrollment Update on Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid for Severe Acute Pain
Ensysce Biosciences Provides Enrollment Update on Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid for Severe Acute Pain
📈 **POSITIVE** • Medium confidence analysis (65%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (85%) **Content type:** Clinical